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Abstract
Background: Computerized clinical decision support systems (CCDSSs) for drug therapy management are
designed to promote safe and effective medication use. Evidence documenting the effectiveness of CCDSSs for
improving drug therapy is necessary for informed adoption decisions. The objective of this review was to
systematically review randomized controlled trials assessing the effects of CCDSSs for drug therapy management
on process of care and patient outcomes. We also sought to identify system and study characteristics that
predicted benefit.
Methods: We conducted a decision-maker-researcher partnership systematic review. We updated our earlier
reviews (1998, 2005) by searching MEDLINE, EMBASE, EBM Reviews, Inspec, and other databases, and consulting
reference lists through January 2010. Authors of 82% of included studies confirmed or supplemented extracted
data. We included only randomized controlled trials that evaluated the effect on process of care or patient
outcomes of a CCDSS for drug therapy management compared to care provided without a CCDSS. A study was
considered to have a positive effect (i.e., CCDSS showed improvement) if at least 50% of the relevant study
outcomes were statistically significantly positive.
Results: Sixty-five studies met our inclusion criteria, including 41 new studies since our previous review.
Methodological quality was generally high and unchanged with time. CCDSSs improved process of care
performance in 37 of the 59 studies assessing this type of outcome (64%, 57% of all studies). Twenty-nine trials
assessed patient outcomes, of which six trials (21%, 9% of all trials) reported improvements.
Conclusions: CCDSSs inconsistently improved process of care measures and seldomly improved patient outcomes.
Lack of clear patient benefit and lack of data on harms and costs preclude a recommendation to adopt CCDSSs for
drug therapy management.
Background
Computerized clinical decision support systems
(CCDSSs) algorithmically apply an electronic knowledge
base to individual patient data to generate and present
suggested actions intended to enhance health and
healthcare [1-3]. CCDSSs for drug therapy management
are used to facilitate evidence-informed medication use
[4], reduce the incidence of harmful medication errors
[5], and improve healthcare system efficiency [2,4,6]. In
this review, we considered any CCDSS that provides
recommendations to healthcare providers regarding the
initiation, modification, monitoring, or discontinuation
of drug therapy, based on the patient’s characteristics.
Systems designed solely to provide advice on the man-
agement of narrow therapeutic index drugs based on in
vivo monitoring and pharmacokinetic principles
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any medium, provided the original work is properly cited.Table 1 Summary of results for CCDSS trials of drug prescribing
Study Methods
score
Indication No. of
centres/
providers/
patients
Process of care
outcomes
CCDSS
Effect
a
Patient outcomes CCDSS
Effect
a
Studies of drug-only interventions
Field, 2009
[17,24]
7 Alerts to promote
appropriate drug
prescribing and
monitoring for patients
with renal insufficiency in
long-term care.
1*/10/833 Appropriate final drug
orders.
0 ... ...
Fortuna,
2009[18]
10 Alerts to consider cost
when prescribing
hypnotics for adults in
primary and urgent care.
14*/257/... Change in hypnotic drug
prescriptions.
+ ... ...
Lo, 2009[20] 10 Alerts to order laboratory
tests when prescribing
new medications in
primary care.
22*/366/
2765
Ordering appropriate
baseline laboratory tests.
0 ... ...
Terrell, 2009
[23]
9 Alerts to avoid
inappropriate prescriptions
in geriatric outpatients
during discharge from
emergency care.
1/63*/5,162 Emergency department
visits resulting in
prescriptions for ≥1 of the
9 targeted inappropriate
medications.
+ ... ...
Gurwitz,
2008[25]
7 Alerts to prevent adverse
drug events in long-term
care.
2*/37/1,118 ... ... Adverse drug events. 0
Hicks, 2008
[26]
7 Reminders for
management of
hypertension in adults in
primary care.
14*/.../2,027 Visits with adherence to
guideline medication
prescribing within one
week.
+ BP controlled. 0
Matheny,
2008[28]
8 Reminders for routine
medication laboratory
monitoring in primary
care.
20*/303/
1,922
Ordering appropriate
laboratory tests.
0 ... ...
Reeve, 2008
[30]
8 Reminders for use of
aspirin in diabetic adults in
primary care.
52*/150/
258,979
Number of aspirin
interventions in diabetic
patients.
+ ... ...
Davis, 2007
[32]
9 Alerts for appropriate
prescribing for upper
respiratory tract infections
in paediatric outpatients.
2/44*/12,195 Prescriptions consistent
with recommendations.
+ ... ...
Heidenreich,
2007[33]
7 Reminders to prescribe b-
blockers for inpatients and
outpatients with reduced
LVEF.
3/50/1,546* Patients with prescriptions
for any b-blocker over nine
months.
+ Survival free of heart
failure hospitalization at
one year.
0
Martens,
2007[34,46]
9 Reminders for prescribing
of antibiotics and drugs
for asthma, COPD, and
dyslipidaemia.
23*/53/3,496 Sum scores for appropriate
prescribing of antibiotics,
statins, cholesterol-
lowering drugs or drugs
for asthma or COPD.
0 ... ...
Peterson,
2007[35]
4 Dosing advice for high-risk
drugs in geriatric patients
in a tertiary care academic
health centre.
1/778/2,981* Ratio of overall prescribed
to recommended doses.
+ ... ...
Raebel,
2007a[37]
8 Alerts to review potentially
inappropriate prescriptions
in ambulatory geriatric
patients.
21/.../59,680* Dispensings of targeted
potentially inappropriate
medications.
+ ... ...
Raebel,
2007b[36]
7 Alerts to avoid teratogenic
drugs in pregnant
ambulatory patients.
.../.../11,100* Dispensed category D or X
drugs.
+ ... ...
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Thomson,
2007[38]
8 Presented information for
treatment decisions about
warfarin or aspirin therapy
for patients with atrial
fibrillation in primary care.
2/2/109* Difference in decision
conflict scale score
immediately post-clinic.
+ Admission to hospital;
adverse events including
transient ischemic attack,
bleeding or stroke
followed by general
practitioner consultation or
admission; patient anxiety.
0
Verstappen,
2007[39]
6 Management of
methotrexate for early
rheumatoid arthritis in
adult outpatients.
6/.../299* ... ... Patients in remission for
≥3 months in first two
years.
+
Feldstein,
2006a[22,41]
10 Alerts to order laboratory
tests when prescribing
new medications in
primary care.
15*/200/961 Baseline laboratory
monitoring completed by
day 25.
+ ... ...
Judge, 2006
[42]
8 Alerts to avoid
inappropriate prescriptions
in long-term care.
1*/27/445 Appropriate prescriber
response to alerts.
0 ... ...
Kattan, 2006
[43]
8 Feedback provided for
management of drug
therapy for severe asthma
in paediatric outpatients.
.../435/937* Time to compliance with
recommended therapy
step; visits resulting in
medication step-up after
step-up recommendation.
+ Maximum symptom days
per two weeks.
0
Palen, 2006
[47]
9 Reminders for laboratory
monitoring based on
medication orders in
primary care.
16/207*/
26,586
Overall compliance with
ordering the
recommended laboratory
monitoring.
0 ... ...
Paul, 2006
[48]
10 Recommendations for
empiric antibiotic
treatment in hospital
inpatients.
15*/.../2,326 Overall rate of appropriate
antibiotic treatment.
+ Duration of hospital stay or
fever; 30-day mortality.
0
Derose, 2005
[50]
7 Reminders to prescribe
ACE-Is, angiotensin
receptor blockers and/or
statins in outpatients with
diabetes or atherosclerosis.
.../1089/
8,557*
Patients with prescriptions
for at least one of ACE-I,
angiotensin receptor
blocker, or statin.
+ ... ...
Heidenreich,
2005[51]
6 Reminders to prescribe
ACE-I or alternative for
inpatients and outpatients
with reduced LVEF.
1/.../600* Patients with prescriptions
for ≥ moderate daily dose
of ACE-I or appropriate
alternative.
0 Mortality; renal function;
creatinine; systolic BP;
diastolic BP.
0
Raebel, 2005
[54]
8 Alerts to order laboratory
tests when prescribing
new medications in
primary care.
.../.../400,000* Laboratory test completed
at time prescription is
dispensed.
+ ... ...
Krall, 2004
[58]
8 Alerts to prescribe of low
dose aspirin therapy in
primary care.
.../100*/
10,972
Provider response to alerts
(prescribe aspirin or
document
contraindication).
+ ... ...
Ansari, 2003
[61]
7 Alerts to prescribe b-
blockers for patients with
heart failure in primary
care.
1/74*/169 Initiated or uptitrated and
maintained on b-blockers;
patients at target b-blocker
dose.
0 Proportion of patients
hospitalised or with
emergency department
visits; deaths.
0
Filippi, 2003
[62]
7 Reminders to prescribe
acetylsalicylic acid or other
antiplatelet agents to
diabetic primary care
patients.
.../300*/
15,343
Antiplatelet drug
prescription.
+ ... ...
Tamblyn,
2003[65]
7 Alerts to avoid
inappropriate prescriptions
in geriatric outpatients.
.../107*/
12,560
Proportion of new
inappropriate prescriptions;
discontinuation of pre-
existing inappropriate
prescriptions.
+ ... ...
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Weir, 2003
[67]
8 Recommendations for
appropriate prescribing of
anti-platelet and/or anti-
coagulant drugs following
stroke or transient
ischemic attack for in- and
out-patients
16*/.../1,952 Number of optimal
treatments provided and
rank of therapy prescribed.
0 Reduction in ischemic and
haemorrhagic vascular
events.
0
Zanetti, 2003
[68]
8 Alert to redose
prophylactic antibiotics
during prolonged cardiac
surgery.
1/.../447* Intraoperative redose of
antibiotics.
+ Surgical-site infection. 0
Christakis,
2001[73]
5 Recommendations for
appropriate prescribing of
antibiotics for otitis media
in paediatric outpatients.
1/38*/488 Antibiotics prescribed for
<10 days.
+ ... ...
Rossi, 1997
[81]
9 Reminders to modify drug
therapy in hypertensive
outpatients receiving
calcium channel blockers
as initial therapy.
1/71/719* Prescription changes from
a calcium channel blocker
to another
antihypertensive agent.
+ ... ...
Rotman,
1996[83]
7 Alerts to prescribe lowest
cost drug alternative for
adult outpatients.
1/37*/... Rate of clinically relevant
drug interactions.
0 ... ...
McDonald,
1980[87]
5 Detection and
management of
medication-related
problems in outpatients.
1/31*/... Response rate for
reminders over five weeks.
+ ... ...
Coe, 1977
[88]
4 Recommendations for
medication management
of hypertension in patients
attending hypertension
clinics.
2/.../116* ... ... Adequate BP control
achieved.
0
McDonald,
1976[89]
2 Recommendations for
laboratory tests to detect
potential medication-
related events in adults
attending a diabetes clinic.
1/.../226* Ordered required tests to
monitor drug effects;
appropriate response to
abnormal measures.
+ ... ...
Studies of multi-faceted interventions
Bertoni, 2009
[16,21]
9 Recommendations for
screening and treatment
of dyslipidaemia in
primary care.
59*/.../3,821 Patients with appropriate
lipid management at
follow-up.
+ ... ...
Gilutz, 2009
[19]
7 Reminders for monitoring
and treatment of
dyslipidaemia in primary
care patients with known
coronary artery disease.
112*/600/
7,448
Appropriate initiation, up-
titration, or continuation of
statin therapy; adequate
lipoprotein monitoring.
+ Change in low-density
lipoprotein level.
+
Javitt, 2008
[27]
6 Patient-specific
recommendations for
detecting and correcting
medical errors in a health
maintenance organization
setting.
1/1378/
49,988*
Resolution for problems
identified by care
considerations by adding
or stopping a drug.
+ ... ...
Quinn, 2008
[29]
6 Recommendations for
management of type 2
diabetes in primary care
using remote glucose
monitoring.
3/26/30* Medications intensified;
Medication errors
identified.
+ Change in HbA1c levels. +
Van Wyk,
2008[31]
10 On-demand and
automatic alerts to screen
and treat dyslipidaemia in
primary care.
38*/80/
92,054
Patients requiring
treatment were treated.
Auto, +
On-
demand,
0
... ...
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Feldstein,
2006b[40]
8 Reminders for monitoring
and treatment of
osteoporosis care in high-
risk women in primary
care who experienced a
fracture.
15/159/311* Received only osteoporosis
medication within 6
months of study start.
+ ... ...
Kuilboer,
2006[44]
10 Recommendations for
monitoring and treatment
of asthma and COPD in
primary care.
32*/40/
156,772
Number of prescriptions
for respiratory drugs.
0 ... ...
Lester, 2006
[45,59]
8 Recommendations for the
management of
dyslipidaemia in primary
care.
1/14/235* Change in statin
prescriptions at 1 and 12
months.
+ Change in low-density
lipoprotein levels.
0
Cobos, 2005
[49]
10 Recommendations for
treatment, monitoring and
follow-up for patients with
dyslipidaemia in primary
care.
42*/.../2,221 Assessed AST/ALT
measurements or creatine
kinase determinations; use
of lipid-lowering drugs in
patients with CHD or
those without CHD and at
high-risk or low-risk.
0 Successful management of
cardiovascular risk.
0
Javitt, 2005
[52]
6 Recommendations for
management of patients
whose care deviates from
recommended practices in
primary care.
.../.../39,462* Compliance with
recommendations to add
or discontinue a
medication.
+ Hospital admissions,
inpatient days, and length
of hospital stay.
+
Plaza, 2005
[53]
9 Recommendations for
cost-effective
management of asthma in
primary care.
.../20*/198 Prescriptions of oral
glucocorticoids
+ St. George Respiratory
Questionnaire total score.
+
Sequist, 2005
[55]
6 Reminders for
management of diabetes
and coronary artery
disease in primary care.
20*/194/
6,243
Receipt of recommended
drugs in diabetes (statins,
ACE-Is in hypertension) or
coronary artery disease
(including aspirin, b-
blocker or statin use).
0 ... ...
Tierney, 2005
[56]
9 Recommendations for the
management of asthma
and chronic obstructive
pulmonary disease in
adults in primary care.
4/266*/706 Suggestions adhered to for
starting, modifying or
stopping bronchodilators;
medication compliance;
patient satisfaction with
physicians and
pharmacists.
0 SF-36 subscale scores;
McMaster Asthma Quality
of Life and Chronic
Respiratory Disease
Questionnaires overall
scores; emergency
department visits;
hospitalizations.
0
Wolfenden,
2005[57]
7 Reminders to provide
smoking cessation
interventions to patients
attending non-cardiac pre-
operative clinic.
1/18/210* Preoperative nicotine
replacement therapy
offered or prescribed.
+ ... ...
Murray, 2004
[60]
5 Recommendations for
treatment of hypertension
in primary care.
4/...*/712 Compliance with all
antihypertensive drug
suggestions; patient
satisfaction.
0 Overall composite quality
of life score.
0
Tierney, 2003
[66]
10 Recommendations for
management of heart
disease in primary care.
4*/115/706 Adherence with care
suggestions to start low-
dose aspirin or
antihyperlipidemic drugs,
or start or increase an
ACE-Is, b-blockers,
diuretics, long-acting
nitrates, or calcium
blockers.
0 Quality of life (score SF-36)
at 12 months; quality of
life (Chronic heart disease
questionnaire overall
health status).
0
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Eccles, 2002
[64,69]
10 Recommendations for
management of asthma or
angina in adults in primary
care.
62*/.../4,506 Prescription of b-blockers
for angina patients.
0
(angina
group)
Overall and disease-specific
quality of life for angina
patients.
0
(angina
group)
Flottorp,
2002[63,70]
9 Recommendations for
management of urinary
tract infections in women
or sore throat in primary
care.
142*/.../... Use of antibiotics for sore
throat and urinary tract
infections.
+ ... ...
Lesourd,
2002[71]
5 Recommendations for
hormonal ovarian
stimulation for infertile
women in a teaching
hospital.
3/4/164* ... ... Pregnancy rate. 0
Selker, 2002
[72]
8 Recommendations for
thrombolytic and other
reperfusion therapy in
acute myocardial
infarction.
28/.../1,596* Patients who had ST-
segment elevation
detected but did not have
acute myocardial
infarction, including those
who received thrombolytic
therapy and those who
had contraindications;
thrombolytic therapy
prescribed within one
hour of acute myocardial
infarction.
0 Death, stroke, or
thrombolysis-related
bleeding events that
required transfusion within
30 days follow-up.
0
Dexter, 2001
[74]
10 Reminders for preventive
therapies in hospital
inpatients.
...*/202/3,416 Hospitalizations with an
order for prophylactic
heparin or aspirin at
discharge (all patients and
only eligible patients).
+ ... ...
McCowan,
2001[75]
8 Recommendations and
reminders for
management of asthma in
primary care.
...*/46/477 Received prescription for
acute asthma
exacerbations.
+ Acute exacerbation of
asthma.
+
Demakis,
2000[76]
7 Reminders for screening,
monitoring, and
counselling in accordance
with predefined standards
of care in ambulatory care.
12*/275/
12,989
Adherence to
recommendations for
international normalised
ratio monitoring in
warfarin users,
anticoagulation in atrial
fibrillation, b-blocker
following myocardial
infarction or change in
non-steroidal anti-
inflammatory drug therapy
following gastrointestinal
bleed.
0 ... ...
Hetlevik,
1999[77-79]
8 Recommendations for
diagnosis and
management of
hypertension, diabetes
mellitus, and dyslipidaemia
in primary care.
56*/56/3,273 ... ... For hypertension and
diabetic patients, change
at 21 months in systolic
and diastolic BP, serum
cholesterol, BMI,
proportion of smokers,
CHD risk score (women or
men), proportion of
patients with
cardiovascular inheritance,
or HbA1c level (diabetic
patients only).
0
Overhage,
1997[80]
8 Recommendations for
corollary orders to prevent
errors of omission for tests
and treatments in general
medicine inpatients.
1*/92/2,181 Pharmacist interventions
with physicians for
significant errors.
+ Days in hospital; maximum
serum creatinine level
during hospital stay.
0
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they are in a complementary in-depth review on thera-
peutic drug monitoring and dosing (submitted to Imple-
mentation Science). Variety in the structure and
function of CCDSSs complicates methodologically
sound investigations and comparisons of these interven-
tions. A CCDSS may be integrated with one or more of
electronic medical records (EMR), computerized provi-
der order entry systems (CPOE) or electronic transmis-
sion of prescriptions to the point of dispensing. CCDSSs
require input of patient data to deliver advice, and this
may be accomplished via integration with patient infor-
mation repositories or by manual entry. Optimally, the
knowledge base of a CCDSS used to generate recom-
mendations is evidence-informed, though this may not
always be the case. Advice may be delivered to many
kinds of providers through a variety of media across
diverse settings of care. Systems may be developed ‘in
house’ to meet the requirements of a specific organiza-
tion or acquired from a commercial vendor.
Decision makers, clinicians, and patients should
require sound evidence of CCDSS benefits, risks and
costs prior to general adoption, as for any health inter-
vention. Randomized control l e dt r i a l s( R C T s )r e p r e s e n t
the gold standard for unbiased comparisons of alterna-
tive interventions [8].
Our previous review [2] included 24 RCTs of a
CCDSS for drug therapy. Of the 13 trials measuring
patient-important outcomes, only one detected benefit
with a CCDSS. Small study size limited detection of
change in patient-important clinical endpoints.
Lack of data on which to base overall conclusions on
the effects of CCDSSs together with the increased pace
of research in the field prompted this update of our pre-
vious review. To aid decision makers and providers, we
evaluated the effects of CCDSSs on process of care and
patient outcomes via cumulative synthesis of relevant
RCTs. This review is one of a series of reviews consider-
i n gt h ee f f e c t so fC C D S S sa c r o s sm u l t i p l ea p p l i c a t i o n
areas (therapeutic drug monitoring and dosing, primary
preventive care, diagnostic test ordering, acute care
management, and chronic disease management).
Methods
This review was conducted in accord with a published
protocol http://www.implementationscience.com/con-
tent/5/1/12[9]. Some trials have been included in more
than one review because they were relevant to more
Table 1 Summary of results for CCDSS trials of drug prescribing (Continued)
Overhage,
1996[82]
10 Reminders to comply with
22 US Preventive Services
Task Force preventive care
measures for hospital
inpatients.
1*/78/1,622 Compliance with
preventive care guidelines
for use of aspirin,
oestrogen or calcium, ACE-
Is, heparin prophylaxis, and
b-blockers.
0 ... ...
Tierney, 1993
[84]
10 Alerts for drug allergies
and drug-drug
interactions, and options
for cost-effective testing in
inpatients.
6*/276/5,219 ... ... Length of hospital stay
and resource use after
discharge (outpatient visits
and readmissions).
0
Mazzuca,
1990[85]
7 Reminders for the
management of type 2
diabetes mellitus in
outpatients.
4*/114/279 Initiation of oral
hypoglycaemic therapy.
0 ... ...
McAlister,
1986[86]
7 Recommendations for
management of
hypertension in primary
care.
50/50*/2,231 Patients receiving
treatment for
hypertension.
0 Diastolic BP ≤90 mmHg on
last visit; days with
diastolic BP ≤90 mmHg;
change in diastolic BP
from baseline.
0
Abbreviations: ACE-I = angiotensin converting enzyme inhibitor; BP = blood pressure; CCDSS = computerized clinical decision support system; CHD = coronary
heart disease; COPD = chronic obstructive pulmonary disease; LVEF = left ventricular ejection fraction.
*Unit of allocation.
aOutcomes are evaluated for effect based on the following hierarchy, with an effect defined as ≥50% of relevant outcomes showing a statistically significant
difference (2p < 0.05):
1. If a single primary outcome is reported, in which all components are applicable, this is the only outcome evaluated.
2. If >1 primary outcome is reported, the ≥50% rule applies and only the primary outcomes are evaluated.
3. If no primary outcomes are reported (or only some of the primary outcome components are relevant) but overall analyses are provided, the overall analyses
are evaluated as primary outcomes. Subgroup analyses are not considered.
4. If no primary outcomes or overall analyses are reported, or only some components of the primary outcome are relevant for the application, any reported
prespecified outcomes are evaluated.
5. If no clearly prespecified outcomes are reported, any available outcomes are considered.
6. If statistical comparisons are not reported and data are insufficient to conduct analyses, ‘effect’ is designated as not evaluated (...).
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the drug therapy review follow.
Research questions
For this review, we were primarily interested in deter-
mining: 1) Do CCDSSs improve performance on drug-
related process of care measures or patient outcomes
compared to usual care? 2) What features or character-
istics of studies or systems are associated with improved
process or patient measures? Based partly on our pre-
vious review [2], we expected studies demonstrating
b e n e f i tf r o mC C D S S sw o u l d :a )b ei n t e g r a t e dw i t ha n
existing EMR or CPOE system (versus a standalone sys-
tem); b) deliver decision support before or during a
patient care encounter where the decision that is being
supported was taken (versus supply of decision support
at any other time); c) actively suggest treatments or
other actions (versus supply general information or
access to general information); d) be used in a patient
care setting affiliated with an academic institution (ver-
sus any other setting); e) have developers of the CCDSS
who were also the study investigators (versus study
investigators not associated with developers); f) measure
intermediate/surrogate patient outcomes (versus patient-
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Additional records identified from 
previous review (n = 86) and 
through other sources (n = 72) 
Records after duplicates removed 
(n = 14,188) 
Records screened 
(n = 14,188) 
Records excluded 
(n = 13,859) 
Full-text articles assessed 
for eligibility 
(n = 329) 
Full-text articles excluded, with 
reasons  (n = 163) 
74 Not RCTs 
50 Did not evaluate CCDSS 
14 Supplemental reports 
9 Severe methodological flaws 
7 Did not meet CCDSS definition 
4 Did not report outcomes of 
interest 
4 Only abstract published 
1 Included in previous review 
Studies included in review 
series 
(n = 166) 
Studies included in this 
review (met drug 
prescribing application 
criteria) 
(n =65) 
Figure 1 Flow diagram of included and excluded studies for the update 1 January 2004 to 6 January 2010 with specifics for drug
prescribing and management*. *Details provided in: Haynes RB et al. [9]. Two updating searches were performed, for 2004 to 2009 and to 6
January 2010 and the results of the search process are consolidated here.
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Page 8 of 17important outcomes); g) describe higher rates of user
satisfaction (versus no or low rates of user satisfaction).
Partnering with decision makers
This review was conducted in partnership with senior
hospital managers and clinical leaders with an academic
research team in the field of knowledge translation,
from healthcare research to clinical practice. Decision
makers provided key input as to the kind of data needed
about CCDSS to drive effective choices and these needs
were incorporated into the research plan where feasible.
Search strategy
The search methods employed have been described in
detail elsewhere [9]. Briefly, a comprehensive search
(2004 to 2010) of major biomedical databases (MED-
LINE, EMBASE, Ovid’s EBM Reviews, and Inspec)
yielded citations for screening. Pairs of reviewers inde-
pendently evaluated each citation and abstract. A third
reader resolved disagreements where necessary. Inter-
reviewer agreement on study eligibility was measured
via unweighted Cohen’sk a p p a( ). Studies from our
previous reviews were carried forward to this review if
they met the inclusion criteria, effectively extending our
search from database inception to 2010.
Study selection
Studies were included for review if they described an
RCT comparing outcomes for a group of providers or
patients using a CCDSS compared with care without the
CCDSS. Non-experimental or quasi-experimental inves-
tigations were excluded. For inclusion, we required that
independent providers or post-graduate trainee (e.g.
medical residents) providers be identified as primary
users of the CCDSS. The intervention CCDSS was
required to provide patient-specific output in the form
of assessments, management options, or recommenda-
tions to the clinical user. Studies were excluded if the
system was used solely by students, only provided sum-
maries of information for patients, only provided feed-
back on groups of patients without feedback about
individual patients, only provided computer-aided
instruction, or were used for image analysis. The six
CCDSS intervention areas in this series of reviews used
a common eligibility screening process [9] to identify
reports of trials of CCDSSs for any purpose. Studies
were then further screened to determine if the system
provided advice regarding drug therapy.
Data extraction
Independent reviewers extracted key data concerning
study methods, CCDSS and population characteristics,
possible sources of bias, and outcomes in duplicate. Pri-
mary authors of each study were asked to review the
extracted data for their study and offer comments on
the extracted data.
Assessment of study quality
Included studies were evaluated on five dimensions of
quality–including concealment of allocation, appropriate
unit of allocation, appropriate adjustment for baseline
differences, adequate follow-up, and appropriate out-
come assessment–to yield a 10-point methods score [9].
Assessment of CCDSS intervention effects
Outcome selection and improvement determinations
Each included trial describing a CCDSS that provided
advice exclusively or predominantly about drug therapy
was classified as drug therapy management only (Rx-
only). Systems that gave advice on drug therapy as part
of a more complex intervention were categorised as
‘multi-faceted’ CCDSSs. Improvement was considered to
have occurred where 50% or more of the selected out-
comes showed a benefit with a CCDSS compared to
control. To determine whether improvement occurred,
all outcomes were selected from the first of: primary,
then pre-specified, then any outcome(s), as defined by
study authors (i.e., if a primary outcome was reported
for a trial this was used to determine improvement to
the exclusion of any other reported outcomes). Where
no outcomes were defined as primary, but the study
reported a sample size calculation for an outcome, we
defined that outcome as primary. These criteria are
more specific than those used in our previous review
[2]; therefore, the assignment of effect was adjusted for
some studies included in the 2005 review. Process of
care outcomes for multi-faceted CCDSS studies were
selected only if they were clearly drug-related. Multi-
faceted systems that reported a patient outcome but did
not report a drug-related process of care outcome inter-
mediary were excluded as non-responsive to our
research questions. Where there were multiple interven-
tion arms, the arm testing the most sophisticated
CCDSS was used to determine improvement. Two
reviewers, working independently and blinded to study
results, classified trials as drug treatment-only or multi-
faceted, and initially identified the outcomes used to
determine improvement, with disagreements resolved by
consensus.
Data synthesis and analysis
Data were summarized using descriptive summary mea-
sures, including proportions for categorical variables and
means (± SD) for continuous variables. For interpreta-
tion, a 2-sided p < 0.05 indicated statistical significance.
For individual studies we report the measures of associa-
tion and p -values reported in the studies.
We did not attempt a meta-analysis because of differ-
ences across studies of participants, settings, disease
Hemens et al. Implementation Science 2011, 6:89
http://www.implementationscience.com/content/6/1/89
Page 9 of 17conditions, interventions, and outcomes. Tests of asso-
ciation between study and CCDSS factors and improved
outcomes were tested using the univariate Fisher’s exact
test. Multivariate analyses were conducted using multi-
nomial logistic regression. All analyses were conducted
using SPSS v. 17.
Sensitivity analyses were conducted to determine if the
class of outcome selected to judge improvement affected
our results. We also identified cluster randomized trials
where units of allocation and units of analysis were
appropriately matched or mismatched. The proportions
of successful trials with matched versus mismatched
units were compared.
Results
A total of 14,952 possibly relevant records were identi-
fied [9]. After excluding duplicate records, 14,188
records were screened to yield 329 articles eligible for
full-text screening. Of those, 166 trials met our criteria
for a CCDSS; Cohen’s  for reviewer agreement on trial
eligibility was 0.93 (95% confidence interval [CI], 0.91 to
0.94). Initially, 71 trials were judged relevant to drug
therapy management. Six of these trials [10-15] were
excluded because they studied a multi-faceted CCDSS
that included drug therapy, but did not report any drug-
related process outcomes. A total of 65 trials reported
in 74 papers were included [16-89] (see Figure 1).
Twenty-four RCTs [60-62,65-67,69,71-76,78,80-89] had
been included in the previous version of our review [2].
Study authors confirmed or supplemented our data
extraction for 53 of 65 included studies (82%) [16-20,
23,25-33,35-39,42-45,47-49,53-55,57,58,60-62,65-72,74--
76,78,81,83-86,88]. Forty-seven included studies contri-
bute outcomes to this review as well as other CCDSS
interventions in the series; four studies [49,56,76,80] to
four reviews, 16 studies [16,19,21,28,40,44,45,53,55,
59,62,64,68,69,74,77-79,82,85,89] to three reviews, and
27 studies [20,22,23,26,27,29,31,32,34,35,39,41-43,46-
48,50,52,54,60,63,66,70,72,75,81,86-88] to two reviews;
but we focused here on drug prescribing-relevant
outcomes.
Summary of trial quality is reported in Additional file
1, Table S1; system characteristics in Additional file 2,
Table S2; study characteristics in Additional file 3, Table
S3; outcome data in Additional file 4, Table S4 and
Table 1, and other CCDSS-related outcomes in Addi-
tional file 5, Table S5.
Study characteristics
Thirty-six trials (55%) [17,18,20,22-26,28,30,32-39,
41-43,46-48,50,51,54,58,61,62,65,67,68,73,81,83,87-89]
described systems classified as drug therapy-only with
the remaining 29 (45%) [16,19,21,27,29,31,40,44,45,49,52,
53,55-57,59,60,63,64,66,69-72,74-80,82,84-86] describing
multi-faceted CCDSSs. Forty-one of 65 included studies
(63%) [16-59,63,68,70] were published since the previous
version of this review. Eleven trials (17%) were published
prior to 2000 [77-89], 16 (25%) trials [58,60-76] between
2000 and 2004 and 38 (58%) trials
[16-34,34-46,46-57,59] after 2004. Most studies (n = 41,
63%) [16-21,23,24,26,28,31-33,38,40,42-44,47,48,55-57,
60,61,63,66-68,70,72-80,82-88] reported public funding;
nine (14%) [29,34,35,45,46,49,50,52,53,59,71] reported
private funding; six (9%) [22,36,37,41,54,64,65,69]
reported public and private funding, and 9 (14%)
[25,27,30,39,51,58,62,81,89] did not disclose a funding
source (see Additional file 3, Table S3). We were able to
determine whether improvement occurred with a
CCDSS for process of care outcomes in 59 studies
[16-24,26-38,40-70,72-76,80-83,85-87,89]; 29 studies
reported patient outcomes [19,25,26,29,33,38,39,43,45,
48,49,51-53,56,59-61,64,66-69,71,72,75,77-80,84,86,88],
and both patient and process outcomes were extracted
from 23 (of 29, 79%) reports [19,26,29,33,38,43,45,48,
49,51-53,56,59-61,64,66-69,72,75,80,86] (Table 1 and see
Additional file 4, Table S4). Twenty [32,33,38,39,43,
48,51-53,56,60,61,66-69,71-73,75,80,84] of 29 (69%) stu-
dies reported a patient important outcome rather than
an intermediate or surrogate outcome [90].
Study quality
Included trials had a median methodological quality
score of 8 (interquartile range [IQR], 2) of a total possi-
ble score of 10. Quality assessments for each trial are
presented in Additional file 1, Table S1. Most included
studies were cluster randomized (n = 44/65, 68%)
[16-26,28,30-32,34,41,42,44,46-49,53,55,56,58,60-67,69,7-
0,73-87], measured an objective outcome or blinded
outcome assessments appropriately (n = 64/65, 98%)
[16-56,58-89], had 80% or greater follow-up of subjects
(n = 56, 86%) [16-38,40-50,52-54,56-59,61-72,
74,76-79,81-87] and 41 (63%) [16,18,20-23,30-34,36-51,
53,54,56-59,63,64,66,68-70,72,74,75,77-82,84] reported
adequate allocation concealment. There was no change
in quality score over time (R
2 = 0.01, p = 0.53).
CCDSS and study characteristics
Additional file 2, Table S2 describes CCDSS users and
Additional file 3, Table S3 describes study settings. A
sum of 8,932 providers (median, 80; IQR, 193) used a
CCDSS to assist with drug management for a total stu-
died population of 1,246,686 patients (median, 2027;
IQR 6960). Most CCDSSs were used by fully-trained
physicians (61/65, 94%) [16-29,31-35,38-56,58-89] and
some by post-graduate medical trainees (19/65, 29%)
[20,23,32,35,55,56,60,66,73,74,76,80-82,84,85,87-89].
After physicians, nurses in advanced practice roles (16/
25 studies, 25%) [16,18,20-22,25-27,33,35,41,42,57,
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[16,18,20,21,25,42,58,63,70,77-79], and pharmacists (8/
65, 12%) [30,35-37,54,56,60,66] were the most common
provider types interacting with CCDSSs. Many systems
r e p o r t e du s eb ym o r et h a no n et y p eo fp r o v i d e r .
CCDSSs were studied in the United States (n = 44, 68%)
[16,18,20-23,26-30,32,33,35-37,40-43,45,47,50-52,54-56,-
58-61,66,68,72-74,76,80-85,87-89], European Union or
European Economic Area countries (n = 13, 20%)
[31,34,38,39,44,46,49,53,62-64,69-71,75,77-79], and
Canada (n = 3, 5%) [17,24,65,86], with the remaining
five studies (8%) [19,25,48,57,67] occurring in multiple
or other countries.
Outpatient settings were studied more often (n = 55,
85%)
[16,18-23,26-41,43-47,49-67,69-71,73,75-79,81,83,85-89]
than other settings of care. Studies were conducted in
both academic settings (n = 34, 52%)
[18,23,25,26,28,33-35,38,39,42,46,48,51,55-57,60,61,66,68-
,71-74,76,80-85,87-89] and outside academic centres (n
= 31, 48%) [16,17,19-22,24,27,29-32,36,37,40,41,43-45,
47,49,50,52-54,58,59,62-65,67,69,70,75,77-79,86].
As presented in Additional file 2, Table S2, the major-
ity of CCDSS systems in our sample were integrated
with an EMR (n = 38/61, 62%) [17,18,20,23-26,28,31,
32,34,40,42,44-47,49,55,56,58-66,68-70,73,74,77-85,87,89-
], delivered feedback via a computer display (n = 44/62,
71%) [17,18,20,23-26,28,30-36,38-40,42,44,46-49,51,
55-58,60-66,68-71,73-76,80,82-84] at the time of care (n
= 53/64, 83%) [16-21,23-26,28,30-35,38,40,42,44,46-
51,53,55-58,60-70,72-85,87-89]. A minority of authors
reported testing a CCDSS with a graphical user
interface (n = 22/25, 88%) [16-18,20,21,23-
25,28,30,31,34,38,40,45,46,55,56,58-60,63,65,70,73,75,83],
pilot-testing the system before the trial (n = 25/45, 56%)
[17-19,24,28,29,31-33,35,38,39,43-45,47,48,55,59,63,66,7-
0-72,74,75,77-79,84], or training users on system use (n
= 29/52, 56%) [16,19,21,26,28,29,31,32,34,35,38,43-47,
53,56-60,62,64-66,69,75-79,83-85]. Data required by the
CCDSS to produce recommendations were most com-
monly entered via EMR link (n = 32/61, 52%)
[17,18,20,24,26,28,31,32,34,40,44-47,49,51,55,56,58-60,62-
-66,68-70,74,80-82,84,85,87,89], followed by provider
entry (n = 23/61, 38%) [16,21,23,25,30,31,34,35,38,39,
46,53,56,63,64,66,67,69-71,73,75,76,80,83,86,88], study
staff (n = 10/61, 16%) [19,39,42,43,48,61,63,70,74,86,89],
and existing staff (n = 8/61, 13%) [36,37,68,72-74,88,89],
although multiple modes of entry were reported in
some studies. Nineteen (29%) [17,18,20,23-25,31,32,34,
35,42,45-47,56,58-60,80,82-84] studies reported using
systems that were integrated with CPOE.
Clinical characteristics
CCDSSs were grouped into one of three categories
representing the primary pharmacotherapeutic purpose
of the system. Systems designed to optimize drug ther-
apy were tested in 47 (72%) trials [16,19,26,27,29-
34,38-40,43-45,48-53,55-58,60-62,66-76,78,81,82,85-88];
systems to prevent adverse drug events accounted for 16
(25%) trials [17,20,23,25,28,35-37,41,42,47,54,65,
80,84,89];while the remaining two (3%) trials [18,83]
focused on drug cost management. Patient populations
were identified (for each system) and consisted of seven
(11%) systems for geriatric patients [17,23,25,
35,37,42,65], three (5%) systems for paediatrics
[32,43,73], four (6%) systems for women’sh e a l t h
[36,40,70,71], and 51 (78%) for adults or unspecified
general populations. We attempted to identify the main
disease state targeted by each system. Sixteen systems
(25%) [17,23,25,27,34,35,37,42,52,58,65,74,76,82-84] were
employed for multiple conditions. Each of the following
disease groupings included three or more systems: cardi-
ovascular disease [26,33,51,60,61,66,69,72,81,86,88] (n =
11, 17%), diabetes mellitus [29,30,50,55,62,78,85] (n = 7,
11%), respiratory disease [43,44,53,56,75] (n = 5, 8%),
dyslipidaemia [16,19,31,45,49] (n = 5, 8%) and infectious
diseases [32,48,68,70,73] (n = 5, 8%). Nine of the
remaining 16 systems [20,28,36,41,47,54,80,87,89] were
designed to prevent or detect drug related problems via
laboratory monitoring.
CCDSS effectiveness
Thirty-seven trials
[16,18,19,21-23,26,27,29-33,35-38,40,41,43,45,48,50,52-5-
4,57-59,62,63,65,68,70,73-75,80,81,87,89] of 59 (63%)
showed improvement in process of care outcomes due
to CCDSS use. No significant difference was found
between Rx-only (23/33) [18,22,23,26,30,32,33,35-38,
41,43,48,50,54,58,62,65,68,73,81,87,89] and multi-faceted
(14/26) [16,19,21,27,29,31,40,45,52,53,57,59,63,70,
74,75,80] CCDSSs for process of care improvement.
Six trials [19,29,39,52,53,75] (9% of all trials, 21% of trials
measuring a patient outcome) demonstrated improved
patient outcomes with CCDSS use compared to usual care
without a CCDSS (see Table 1). Four [39,52,53,75] of the
six trials demonstrating improved patient outcomes mea-
sured patient-important outcomes. No significant differ-
ence in improvement was found between drug-only (1/12)
[39] and multi-faceted (5/17) [19,29,52,53,75] CCDSSs.
Results did not significantly vary, for either process of
care or patient outcomes, by the type of outcome (pri-
mary, pre-specified, or other) selected to determine
improvement.
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also showed improvement in measured process of care
outcomes.
The proportion of successful trials was not signifi-
cantly different between cluster trials where units of
allocation were mismatched with units of analyses (7/15
for process and 1/5 for patient outcomes) compared
with non-cluster trials or cluster trials with an appropri-
ately adjusted analysis (29/43 for process (p=0.22) and
5/24 for patient outcomes (p = 1)).
Predictors of success
This analysis was limited by incomplete data in many
studies and by limited power for multivariate analysis.
In univariate analysis, CCDSSs not integrated with an
EMR were more likely to improve process of care out-
comes, 16/20 (80%) non-integrated systems showed
improvement versus 18/35 (51%) improved with EMR
linkage (p=0.03). The same trend was seen with inte-
gration of EMR and CCDSS for patient outcomes (6/15
(40%) improved outcomes without EMR link versus (0/
13 (0%) with EMR link, p = 0.017). This association
between EMR integration and CCDSS failure was not
statistically significant via multivariate regression.
Improvement in process of care or patient outcomes
was not affected by integration with CPOE, timing or
method of decision support delivery, or method of data
entry. Improvement in process or patient outcomes did
not vary by country, provider type, and outpatient versus
other settings of care. Systems trialed outside of academic
settings were more likely to improve patient outcomes
(5/12 (42%) outside academic settings versus 1/17 (6%) in
academic settings, p = 0.03). This finding was not repli-
cated in multivariate analyses. Investigators who devel-
oped the system under study were not significantly more
likely to see improvement with a CCDSS than investiga-
tors studying systems developed by unrelated parties (p =
0.56 for process and p = 1 for patient outcomes). Patient
important outcomes were as likely as surrogate outcomes
to show improvement with a CCDSS. Post hoc,n o n eo f
primary disease state, primary patient population, or
pharmacotherapeutic purpose predicted success. We
found no association between the presence of a sample
size calculation and success or between number of trial
participants and success. The proportion of studies
added in this update demonstrating benefit with CCDSS
for process of care and patient outcomes increased com-
pared with studies included in the previous review ver-
sion, although this trend was not statistically significant.
Costs and practical process related outcomes
Harms
Potential or actual harm resulting from CCDSS use was
explicitly discussed in four (6%) [16,21,36,68,89]
included studies (see Additional file 5, Table S5). Two
studies reported quantitative data regarding harms. Rae-
bel et al. [36] reported a trial stopped early due to a
high rate (40%) of clinically inappropriate reminders
generated by the CCDSS. Zanetti et al. [68] reported
one inappropriate redose of intra-operative prophylactic
antibiotic for every 137 appropriate redose reminders.
Costs
Some information on financial or economic costs asso-
ciated with CCDSS was reported for 15 (23%)
[17,19,24,27,43,48,49,52,53,56,57,60,66,80,83,84] trials
(see Additional file 5, Table S5). A formal cost-effective-
ness analysis for a patient outcome was performed in
o n l yo n ec a s e[ 5 3 ] .T w e l v et r i a l sc o m p a r e dd i r e c t
healthcare costs between CCDSSs and control groups
with mixed results: significantly decreased costs were
observed in six trials [27,43,48,49,52,84], no significant
change in five trials [53,60,66,80,83], and significantly
increased costs in one trial [56].
User satisfaction
Fifteen authors reported on user satisfaction with the
CCDSS studied (see Additional file 5, Table S5)
[18,19,29,30,33,39,55,57,63,64,67,69,70,75,77-79,83,84].
All attempts to measure user satisfaction were con-
ducted via surveys and the properties of the measure
used were only discussed in a single trial [55]. Survey
response rates ≥50% were found in eight studies. Of
these eight, six reported [18,29,33,55,57,84] that ≥70% of
respondents thought the CCDSS improved care, was
useful, or should be continued in use. Satisfaction data
from the other two trials [77-79,83] suggested users
could not or would not use the CCDSS due to technical
or user interface problems. Available data on user satis-
faction were too sparse to determine if satisfaction
impacted study results.
Discussion
We reviewed 65 RCTs of CCDSSs for drug therapy
management reported over a 34-year span. Most trials
measured process of care outcomes and results sup-
ported the use of CCDSSs to improve these outcomes
in a majority of cases (improvement was based on at
least 50% of the relevant study outcomes being statisti-
cally significantly positive). However, while nearly one-
half of (29 studies) included studies measured a patient
outcome, only a small proportion demonstrated any
direct benefit to patients. While improvement in process
outcomes could lead to benefits for patients, no consis-
tent link was observed here. In the absence of data
needed for an economic analysis, improved process of
care measures alone are not sufficient to recommend
adoption of these systems. The success rates we found
for processs of care (64%) and clinical outcome mea-
sures (21%) are similar to those in our previous review
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reviews of computerized decision support (57% and 30%
respectively) by Jaspers et al. [91].
Several possible predictors of CCDSS success were
examined. In most cases, these ap r i o r ifactors did not
explain success or failure across included studies. Our
previous review [2] concluded that successful trials of
CCDSS were more likely to have been conducted by the
developers of the system under study. In our current
review, no such association was noted. Previously, a sig-
nificant trend towards increased study quality over time
was noted, but not replicated in this update, and we
attribute this to a more restrictive inclusion criterion
(randomized controlled trials). Counter to our expecta-
tions, we found that integration of CCDSSs with EMRs
and use in an academic setting was associated with
CCDSS failure. This trend was not statistically signifi-
cant when tested using multi-variate techniques and so
we are unable to determine whether this finding repre-
sents a true association or is better explained by the
lack of power in our multi-variate analysis. We report
these findings as hypothesis generating only and suggest
they be examined in future.
Compared with the review of Kawamoto et al. [92],
we did not find that automatic provision of advice as
part of the existing clinical workflow predicted CCDSS
success. Because both the current analysis and that of
Kawamoto were underpowered to detect such associa-
tions, we have refrained from drawing any conclusions
in this regard.
Prospective data on the possible harms of CCDSSs are
needed to facilitate informed adoption decisions. Only
two trials quantitatively reported on harm from CCDSSs
[36,68] with one trial ending early due to increased risk
of harm with the CCDSS. We suggest this absence of
evidence of harm should not be taken as proof that
CCDSSs are safe to employ for drug management in
patient care.
Strengths and limitations of review
The results of our review should be interpreted with
consideration of methodological strengths and limita-
tions, including steps taken to mitigate the risk of bias.
We based our review on the strongest studies available,
RCTs. Reviews are necessarily retrospective and we
employed multiple methods to limit the introduction of
bias, including: duplicate study eligibility assessment,
duplicate data abstraction, solicitation of study author
feedback on abstracted data, and objective selection of
outcomes used to determine improvement. We cannot
exclude the possibility that a different method of select-
ing outcomes from each study to measure improvement
could lead to different results, although sensitivity ana-
lyses did not suggest this to be the case. Several pre-
specified analyses of possible predictors of system suc-
cess were conducted. Several analyses demonstrated sta-
tistically significant results using univariate techniques
that were not substantiated using a multi-variate model.
Therefore, the few associations we reported between
possible predictors of success and improved outcomes
with CCDSS should be interpreted with caution.
We have relied upon vote counting as our method of
obtaining an estimate of how often CCDSS for drug
therapy management improve process or patient out-
comes. Significant limitations to this approach as
d e s c r i b e db yH e d g e s[ 9 3 ]i n c l u d eat e n d e n c yt oi n f l a t e
type II error and inadequate incorporation of the effect
of unequal study sizes in overall results. The heteroge-
neity between studies included in our review precluded
the use of more robust combination techniques. Formal
assessment for publication bias using funnel plots was
not possible with the vote-counting technique.
The effectiveness of any CCDSS will be determined in
part by the efficacy of the underlying action suggested
by the system. Where no benefit was detected with a
particular CCDSS, we cannot exclude the possibility that
the negative finding is due to a lack of efficacy of the
intervention suggested by the system. Measurement of
the concordance between decision advice given and fol-
lowed would be a useful measure to address this issue.
These outcomes were included in our analyses of pro-
cess of care outcomes. It does not necessarily follow,
however, that an effective CCDSS that recommends the
appropriate prescription of an efficacious intervention
will necessarily improve patient care. A multitude of
intervening factors (e.g. patient non- or over-adherence
or new errors introduced by CCDSS) may mitigate (or
exaggerate) estimates of CCDSS effectiveness.
Finally, the systems reviewed constitute a heteroge-
neous group with differing functionality and clinical
intent. While we have attempted to usefully divide the
systems for the reader, we acknowledge other divisions
were possible.
Implications for practice and research
Because CCDSSs have not been shown to reliably and
positively impact patients, and in the absence of useful
data on potential harms, costs, and clinician impacts, we
cannot recommend the general adoption of CCDSSs for
drug therapy management. It is possible that these sys-
tems are still evolving and success will improve with
time. Clearly further innovation is needed if these sys-
tems are to be dependably useful in clinical practice.
Rigorous trials of these innovations will be necessary,
and we suggest that future research explicitly address
patient outcomes, including potential harms, and costs
and adverse clinician impacts of CCDSSs. Given the
availability of effective non-computerized approaches for
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future studies may wish to incorporate these interven-
tions as active comparators to CCDSSs.
Conclusions
CCDSSs inconsistently improved process of care mea-
sures and seldom improved patient outcomes. Lack of
clear patient benefit and lack of data on harms and
costs preclude a recommendation to adopt CCDSSs for
drug therapy management.
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